Skip to main content
v2026.11,986 entries · CC-BY 4.0
CASRAIAsk CASRAI · AI assistant for researchAsk a research question. Answers come with their sources.Funder rules, compliance, methods and publishing. Answers link the sources they rest on.

Editorial · CASRAI · Funding lifecycle and financial vocabulary

HHS, VA and ARPA-H Announce Up to $4.9M for Single-Molecule Ibogaine PTSD Research Groundwork

HHS and ARPA-H announced up to $4.9M for single-molecule ibogaine groundwork, establishing manufacturing and data foundations ahead of any US trials.

Published 16 Nov 2026· 7 minute read

Ask CASRAI · free to try

Ask about this story

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

CASRAI is the reference for research administration — bookmark it for the next question.

On November 12, 2026, the U.S. Department of Health and Human Services (HHS), the Department of Veterans Affairs (VA), and the Advanced Research Projects Agency for Health (ARPA-H) announced up to $4.9 million in federal awards to lay the regulatory, chemical, and analytical groundwork for studying single-molecule ibogaine hydrochloride as a potential treatment for post-traumatic stress disorder (PTSD) and other serious mental illnesses.

Federal awards target foundational ibogaine research

Announced by HHS Secretary Robert F. Kennedy, Jr. and VA Secretary Doug Collins the day after Veterans Day, the five-year ARPA-H initiative represents the federal government’s first structured investment aimed at transitioning ibogaine—an alkaloid historically extracted from the West African shrub Tabernanthe iboga—into a standardized, pharmaceutical-grade therapeutic candidate. Alongside the ARPA-H awards, HHS announced that the National Institute of Mental Health (NIMH) published a separate $20 million Notice of Funding Opportunity (NOFO) to establish a cooperative research network evaluating rapid-acting psychotropic interventional drugs, including ketamine and psilocybin.

Federal officials and agency notices underscored a critical regulatory distinction: the initial ARPA-H awards do not fund direct patient treatment, nor do they authorize immediate human clinical trials in the United States. Instead, the funding is strictly earmarked for pre-trial translational prerequisites, including synthetic chemistry standardization, toxicological characterization, cardiac safety data aggregation, and the preparation of comprehensive data packages required to support future Investigational New Drug application filings with the U.S. Food and Drug Administration (FDA).

Award recipients and technical scope

The $4.9 million ARPA-H commitment is divided between two primary industry and clinical partners, each assigned a distinct operational role in establishing the translational pipeline:

  • Mark Cuban Cost Plus Drug Company, PBC: Awarded funding to establish the regulatory, chemical, and engineering foundations necessary to produce a domestically manufactured, single-molecule ibogaine hydrochloride product. Cost Plus Drug Company will focus on scalable synthetic pathways and quality control systems aligned with rigorous Good Manufacturing Practice standards, aiming to prevent reliance on wild-harvested botanical extracts and ensure supply-chain transparency and affordability.
  • Beond, Inc.: Partnering with ARPA-H to provide a structured, de-identified real-world clinical dataset derived from 250 patients previously treated with ibogaine at its medical facility in Cancún, Mexico. Subject to rigorous retrospective de-identification protocols, this dataset encompasses continuous electrocardiogram (ECG) telemetry, adverse event logs, and longitudinal psychometric outcomes tracking PTSD, depression, and substance use disorder symptoms.

The following table compares the two concurrent federal funding tracks announced by HHS:

Programme Dimension ARPA-H Ibogaine Groundwork Awards NIMH Rapid-Acting Psychotropics Network
Funding Ceiling Up to $4.9 million over five years $20 million (Notice of Funding Opportunity)
Lead Lead Agencies ARPA-H, in coordination with VA and FDA NIMH and National Institutes of Health (NIH)
Primary Scope Synthetic chemistry, manufacturing controls, safety telemetry Multicenter clinical trials and mechanistic evaluation
Target Substances Single-molecule ibogaine hydrochloride Ketamine, esketamine, psilocybin, novel neuroplastogens
Clinical Trial Status No US human trials authorized; IND preparation only Active protocol execution under cleared FDA INDs
Primary Recipients Cost Plus Drug Company, PBC and Beond, Inc. Extramural academic medical centers and research consortia

Regulatory barriers and cardiac safety context

Under federal law, ibogaine remains classified as a Schedule I controlled substance under the Controlled Substances Act, a category designated for compounds with a high potential for abuse and no accepted medical use in the United States. While observational studies and overseas clinic reports have suggested potential efficacy in interrupting opioid withdrawal and mitigating treatment-resistant PTSD, clinical translation in the United States has historically stalled due to serious cardiotoxicity concerns.

Pharmacologically, ibogaine and its primary metabolite, noribogaine, are known potent blockers of the hERG (human Ether-à-go-go-Related Gene) potassium channel (Kv11.1), which can cause marked prolongation of the cardiac QTc interval and elevate the risk of fatal ventricular tachyarrhythmias, including torsades de pointes. By funding high-resolution ECG analysis from Beond’s patient cohorts and coupling it with single-molecule chemical characterization from Cost Plus Drug Company, ARPA-H intends to establish the exact pharmacokinetic and electrophysiological boundaries required before any interventional trial can be cleared by the FDA.

Furthermore, previous academic investigations were frequently constrained by chemical heterogeneity in botanical preparations, which contain variable mixtures of active alkaloids such as ibogaline and ibogamine. ARPA-H’s focus on a single-molecule synthetic salt aims to eliminate natural batch variability and provide the reproducible analytical specifications demanded by current FDA drug development standards.

Agency and industry reaction

In public remarks accompanying the release, HHS Secretary Robert F. Kennedy, Jr. framed the investment as an essential response to the mental health crisis affecting military veterans. Kennedy stated that federal agencies must pursue unconventional, high-impact approaches for conditions that have resisted standard therapeutic options, while maintaining uncompromising scientific rigor.

VA Secretary Doug Collins highlighted the urgent need for new therapies for veterans suffering from severe, persistent post-traumatic stress and substance use disorders, pointing out that existing standard-of-care pharmacotherapies often yield limited efficacy or intolerable side effects. Collins emphasized that inter-agency collaboration between the VA, ARPA-H, and FDA is essential to ensure that safety parameters are established systematically before any veteran clinical trials are considered.

Representatives from the Mark Cuban Cost Plus Drug Company noted that their mandate focuses on engineering cost-effective domestic manufacturing pathways to prevent monopolistic pricing structures should the compound eventually achieve regulatory clearance. Meanwhile, leadership at Beond stated that contributing de-identified observational data provides regulatory authorities with essential real-world safety benchmarks without exposing domestic patients to unmonitored risk.

Implications for universities and research offices

While the ARPA-H contracts are directed to specific industry partners, the announcement carries substantial strategic and administrative implications for academic institutions and university research offices:

  • Funding Opportunities: University sponsored programs offices should recognize that the $4.9 million ARPA-H investment is not an open grant competition for university PIs. In contrast, the concurrent $20 million NIMH notice of funding opportunity represents an immediate extramural grant target for academic medical centers specializing in psychiatric clinical trials and rapid-acting psychotropic mechanisms.
  • Regulatory Dossier Access: Academic investigators aiming to conduct future translational research on ibogaine derivatives may eventually benefit from the Drug Master Files (DMFs) and chemistry, manufacturing, and controls data generated by this initiative. Cost Plus Drug Company’s synthesis groundwork could establish an accessible domestic source of clinical-grade API, which has historically been a fatal bottleneck for university-led IND sponsorships.
  • Data-Sharing Governance: The integration of Beond’s foreign clinical data underscores the increasing use of retrospective real-world datasets in regulatory submissions. University compliance officers reviewing cross-institutional data-sharing agreements should note the stringent de-identification and data-provenance protocols required to submit foreign observational health data to federal agencies.
  • Clinical Trial Design Standards: When ibogaine research eventually progresses toward early clinical trial phases in domestic settings, institutional review boards (IRBs) and clinical research centers will require intensive cardiac monitoring infrastructure, including continuous telemetry and strict exclusion criteria for underlying cardiovascular vulnerabilities.

What happens next

Over the next 12 to 24 months, the ARPA-H initiative will focus on establishing chemical synthesis milestones and validating batch-to-batch analytical purity for single-molecule ibogaine hydrochloride. Concurrently, data scientists will process and model the 250-patient retrospective dataset from Beond to quantify QTc interval dynamics and identify risk factors associated with adverse events.

Applications for the complementary $20 million NIMH rapid-acting psychotropics network will proceed through standard peer review in early 2027, with network awards anticipated prior to the end of the fiscal year. Any future move by ARPA-H or academic sponsors to initiate human clinical trials involving ibogaine within the United States will require formal IND clearance from the FDA and Schedule I research registration and manufacturing quotas from the Drug Enforcement Administration (DEA).

Sources

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →